medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2013, Number 4

<< Back Next >>

Revista Cubana de Salud Pública 2013; 39 (4)

Strategies for the prevention of type I diabetes mellitus

Licea PME, González CTM

Language: Spanish
References: 58
Page:
PDF size: 200.31 Kb.


ABSTRACT

Type I diabetes mellitus shows long chronic progressive phase that is now predictable in most of individuals. Recent advances in the understanding of autoimmune etiology of this type of diabetes warrant the implementation of novel methods of immunological interventions. This paper was aimed at reviewing the most relevant aspects on the prevention of type I diabetes mellitus and probable strategies. The intervention measures covered the following immunological methods: deprivation of bovine proteins, plasmapheresis, insulin-based therapy, oral administration of insulin and GAD antigen; use of immunosupressors, immunomodulators and semi-specific immunotherapies. Non-immunological treatments have been used such as use of nonsteroidal anti-inflammatory or antioxidant drugs prior to onset of intolerance to glucose, and the presence of vascular complications. Several trials on possible preventive treatments for type I diabetes mellitus are being performed, but none of them has been so far enough safe and efficient in a convincing way; the rational use of new and potent immunosuppresors or immunomodulators is an attractive procedure to prevent the development and progression of the autoimmune process that characterizes this disease in "high risk" individuals.


REFERENCES

  1. Skyler JS. Etiología, patogenia y tratamiento de la diabetes mellitus tipo En: Lavin N, editor. Endocrinología y Metabolismo. 3ra ed. Madrid: Ediciones Marbán; 2003. p. 601-9.

  2. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am. 2005;52:1553-78.

  3. Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, et al. The Trial Net Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes.2009;10:97-104.

  4. Concannon P, Chen WM, Julier C, Morahan G, Akolkar B, Erlich HA, et al. Genomewide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes. 2009;58:1018-22.

  5. Bingley PJ, Bonifacio E, Ziegler AG, Schatz D, Atkinson MA, Eisenbarth GS. Proposed guidelines on screening for risk of type 1 diabetes. Diabetes Care. 2001;24:398-403.

  6. Razack NN, Wherrett DK: Type 1 diabetes: New horizons in prediction and prevention. Paediatr Child Health. 2005;10:3.

  7. CaillatZucman S, Bach JF. Genetic predisposicion to IDDM. Clin Rev Allergy Immunol. 2000;19:227-46.

  8. Steck AK, Zhang W, Bugawan TL, Barriga KJ, Blair A, Erlich HA, et al. Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR,DQ genotypes? Diabetes. 2009;58:1028-33.

  9. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care. 2004;27:2695-700.

  10. Razack NN, Wherrett DK. Type 1 diabetes: New horizons in prediction and prevention. Paediatr Child Health. 2005;10:35-7.

  11. Vidal J, Fernandez-Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R, et al. Effects or nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care. 2000;23:360-4.

  12. Carla JG, Leonard C. H. Perspectives in Diabetes. In: Guidelines for Intervention Trial in Subjects with Newly diagnosed type 1 Diabetes. Diabetes. 2003;52:1-7.

  13. Eisenbarth GS, Polonsky K S, John B. Buse type 1 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of Endocrinology. 11th ed. Philadelphia: ELSEVIER; 2008. p. 1391-400.

  14. Issermann B, Ritzel R, Zorn M, Schiling T, Nawroth PP. Autoantibodies in diabetes Mellitus: Current utility and perspectives. Exp Clin Endocrinol Diabetes. 2007;115:483- 90.

  15. Syler JS. Can Type-1 diabetes be prevented? Intern Diab Monit. 1992; 4:1-6.

  16. Neifing JL, Greenbaum CJ, Kahn SE, Mc Culloch DK, Barmeier H, Lernmark A, et al. Prospective evaluation of beta cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients. Metab Clin Exp. 1992;42:482-6.

  17. Harrinson LC, Honeyman MC, De Aizpurua HJ, Schmidli RS, Colman PG, Tait BD, et al. Inverse relation between humoral and cellular immunity to gluthamic acid decarboxylase in subjects at risk of IDDM. Lancet. 1993;34:1365-9.

  18. Vardi P, Crisa L, Jackson RA, Dumont R, Wolfsdorf Jl, Einhorn D, et al. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater the first percentile in islet cell antibody positive relatives of Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1991;34:93-102.

  19. Kobayashi M, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, et al. Inmunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780-8.

  20. Licea ME, Romero JC. Estrategias para la prevención de la diabetes mellitus. En: Licea ME, editor. Tratamiento de la diabetes mellitus. 2da ed. Brasilia: Editorial IDEAL; 1995. p. 9-19.

  21. Drash AL, Arsianian SA. Can insulin-dependent diabetes mellitus be cured of prevented ? Pediatr Clin North Am. 1990;37:1467-87.

  22. Reijonen H, Concannon P. Genética de la diabetes tipo 1. En: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, editors. Joslin´s Diabetes mellitus. 14 ed. Boston: Lippincott/Williams and Wilkins; 2005. p. 355-70.

  23. Baekkeskov S, Aasloot MJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64k autoantigen in insulin-dependent diabetes as GABAsynthesizing glutamic acid decarboxylase. Nature. 1990;327:151-6.

  24. Velloso LA, Kaempe O, Hallberg A, Christmanson L, Betsholtz C, Karlsson FA. Demonstration of GAD-65 as the main immunogenic isoform of the glutamic acid decarboxylase in Type-1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest. 1993;91:2084-90.

  25. Wilkin T. Antibody markers for Type-1 diabetes: the issues. Trends Endocrinol Metab. 1990;1:204-11.

  26. Drell DW, Notkins AL. Multiple. Immunological abnormalities inm pacient wich Type-1 (insulin- dependent) diabetes mellitus. Diabetologia. 1988;30:132-43.

  27. Wang Y, Hao L, Lafferty KJ. The pathogenesis of inmunologically mediated diabetes. In: Ginsberg-Fellner F, McEvoy RC, editors. Autoinmunity and the Pathogenesis of Diabetes. Endocrinology and Metabolism Series. Heidelberg: Springer- VerLag; 1989. p. 184-205.

  28. Jackson RA, Soeldner JS, Einsenbarth GS [abstr]. Testing the dual parameter model for predicting time to diabetes. Clin Res. 1989;37:57.

  29. Karjalainen J, Martin JM, Knip M, Ilonen L, Robinson BM, Savilahti E, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:302-7.

  30. Martin JM, Trink KB, Daneman D, Dosch HM, Robinson BH. Milk proteins in the: etiology of insulin- dependent-diabetes mellitus (IDDM). Ann Med. 1991;23:447-52.

  31. Mauricio D. Estado actual de la prevención de la diabetes mellitus tipo 1. Av Diabetol. 2001;17:145-9.

  32. Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008;1150:190-6.

  33. Paronen J, Knip M, Savilahti E, Virtanen SM, Ilonen J, Akerblom H; The Finnich Trial to Reduce IDDM in the Genetically at risk Study Group. Effect of cow´s milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Diabetes. 2000;49:1657- 65.

  34. Naik RG, Palmer JP. Preservation of -cell functions in type 1 diabetes. Diabetes Rev. 1999;7:154-82.

  35. Keller LJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet. 1993;341:927-8.

  36. Keller RJ, Jackson RA, Eisenbarth GS [abstr]. Beta cell function in islet cell antibody (ICA). Positive first degree relatives treated with insulin. Diabetes Res Clin Pract. 1991;14:s84.

  37. Keller RJ, Jackson RA, Eisenbarth GS [Abstr]. Preservations of beta cell function in islet cell antibody (ICA). Positive first degree relatives treated with insulin. Diabetes. 1992;41:13.

  38. Type 1 Diabetes Study Group. Diabetes Prevention Trial. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685-9.

  39. Type 1 Diabetes Study Group. Diabetes Prevention Trial. Effects of oral insulinin relatives of patients with type 1 diabetes. Diabetes Care. 2005;28:1068-76.

  40. Thornpson HSG, Staines NA. Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today. 1990;11:396-9.

  41. Yale JF, Grose M, Roy RD, Seemayer TA, Marliss EB. Immunological and metabolic concomitants of cyclosporin prevention of diabetes in BB rats. Diabetes. 1987;36:749- 57.

  42. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, et al. Cyclosporin increased the rate and length of remission in insulin-dependent diabetics of recent onset: result of a multicentre double-blind trial. Lancet. 1986;2:119-23.

  43. Bougneres PF, Carel JC, Castaño L, Boitard C, Gardin JP, Landais P, et al. Factors associated whit early remission of Type 1 diabetes in children whit cyclosporine. N Engl J Med. 1988;318:663-70.

  44. Riley WJ, Maclaren NK, Spillar R. Reversal of deteriorating glucose tolerance with azathioprine in prediabetes. Transplant Proc. 1986;18:819-22.

  45. Miyagowa J, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C, Otsuka A, et al. Preventive effect of new inmunosuppressant FK-506 on insulinitis and diabetes in nonobese diabetic mice. Diabetologia. 1990;33:503-5.

  46. Harrinson LC, Honeyman M, Steele C, Graham M [abstr]. Photophoresis trial in IDDM: an interim report. Proc Aust Diabetes Soc. 1992:91.

  47. Smilek DE, Luck CB, McDevith HD. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease. Immunol Rev. 1990;118:37-71.

  48. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692-8.

  49. Matsuo S, Mullen Y, Wicker LS, Peterson LB, Nagata M, Tsunoda J, et al. Prolongation of islet isograft survival in diabetic NOD mice by anti L3T4 and anti Lyt2 monoclonal antibodies. Tranplant Proc. 1990;22:880-1.

  50. Cohen IR. T-cell Vaccination in immunological disease. J Intern Med. 1991;230:471-7.

  51. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarvis S. Preventive and therapeutic effect of large dose nicotinamide injection on diabetes 51 associated whit insulinitis. An observación in non obese diabetic (NOD) nice. Diabetes. 1982;31:749-53.

  52. Lampeter EF, Klinghhammer A, Scherbaum WA. The Deutsch Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes. 1998;47:980-4.

  53. European Nicotidamide Diabetes Intervention Trial (ENDIT) Group. A randomized controlled trial of intervention before onset of type 1 diabetes. Lancet. 2004;363:925- 31.

  54. Vague P, Picg R, Bernal M, Lassmann-Vague V, Vialettes B. Effect of nicotinamide treatment on the residual insulin secretion in Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1989;32:316-21.

  55. Buzzetti R, Nistico L, Giovannini C, Chersi A, Sorrentino R. HLA-DQA1 and DQB1 gene polimorphisms in Type 1 diabetic patients from central Italy and their use for risk prediction. Diabetes. 1993;42:1173-8.

  56. Carel JC, Biotard C, Bougneres PF. Decreased insulin response to glucose in islet cell antibody-negative sibling of Type I diabetic children. J Clin Invest. 1993;92:509- 13.

  57. Gomis de Barbará R, Brugnara L. Prevención de la diabetes mellitus. En: Gomis de Bárbara R, Rovira A, Felíu JE, Oyarzábal M, editors. Tratado SED de diabetes mellitus. Madrid: Panamericana; 2007. p. 651-5.

  58. Eisenbarth GS. Diabetes mellitus tipo 1. En: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, editores. Joslin´s Diabetes mellitus. 14 ed. Boston: Lippincott/Williams and Wilkins; 2005. p. 399-424.




2020     |     www.medigraphic.com